454 related articles for article (PubMed ID: 25016222)
1. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
[TBL] [Abstract][Full Text] [Related]
2. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
Sieghart W; Hucke F; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Trauner M; Peck-Radosavljevic M
Hepatology; 2013 Jun; 57(6):2261-73. PubMed ID: 23316013
[TBL] [Abstract][Full Text] [Related]
3. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.
Hucke F; Sieghart W; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M
J Hepatol; 2014 Jan; 60(1):118-26. PubMed ID: 24012941
[TBL] [Abstract][Full Text] [Related]
4. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
[TBL] [Abstract][Full Text] [Related]
6. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
[TBL] [Abstract][Full Text] [Related]
7. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular Carcinoma.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Ida H; Minami Y; Sakurai T; Nishida N; Kitano M; Kudo M
Oncology; 2015; 89 Suppl 2():4-10. PubMed ID: 26584030
[TBL] [Abstract][Full Text] [Related]
9. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
[TBL] [Abstract][Full Text] [Related]
10. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
[TBL] [Abstract][Full Text] [Related]
11. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching.
Min YW; Lee JH; Gwak GY; Paik YH; Lee JH; Rhee PL; Koh KC; Paik SW; Yoo BC; Choi MS
J Gastroenterol Hepatol; 2014 May; 29(5):1043-8. PubMed ID: 24863186
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
[TBL] [Abstract][Full Text] [Related]
14. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
[TBL] [Abstract][Full Text] [Related]
15. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
[TBL] [Abstract][Full Text] [Related]
16. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function.
Hsu KF; Chu CH; Chan DC; Yu JC; Shih ML; Hsieh HF; Hsieh TY; Yu CY; Hsieh CB
Eur J Radiol; 2012 Mar; 81(3):466-71. PubMed ID: 21376495
[TBL] [Abstract][Full Text] [Related]
17. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
[TBL] [Abstract][Full Text] [Related]
18. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
20. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI
J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]